|
|
|
|
| LEADER |
02886nam a2200325 u 4500 |
| 001 |
EB001897189 |
| 003 |
EBX01000000000000001060194 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200523 r ||| eng |
| 245 |
0 |
0 |
|a Axicabtagene ciloleucel for large B-cell lymphoma: Health technology assessment introduction and clinical review protocol
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Health technology assessment introduction and clinical review protocol
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c May 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (29 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Immunotherapy, Adoptive
|
| 653 |
|
|
|a Lymphoma, Large B-Cell, Diffuse / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Technology Assessment, Biomedical
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Antineoplastic Protocols
|
| 653 |
|
|
|a Antigens, CD19 / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH optimal use report
|
| 500 |
|
|
|a "PROSPERO registration number: CRD42019119293."
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK550126
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 600
|
| 520 |
|
|
|a Lymphomas are blood cancers that develop in the lymphatic system and are divided into Hodgkin lymphoma and non-Hodgkin lymphomas (NHL). NHLs are categorized as B-cell, Tcell, or natural killer/T-cell lymphoma, depending on the cell implicated in the disease. While B-cell NHLs display a wide range of clinical behaviours, there are several subtypes that have a roughly similar clinical course and are treated in a similar manner. These subtypes include diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. In Canada, NHL accounts for 83% of all cases of lymphomas. In this context, axicabtagene ciloleucel is a chimeric antigen receptor (CAR) T-cell therapy that has been approved by the FDA for use in "adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma." As Health Canada approval for axicabtagene ciloleucel is pending, the final indication remains to be confirmed; however, based on the available evidence and existing approvals for this therapy (i.e., by the FDA and the European Union), potentially eligible indications are these types of relapsed or refractory large B-cell lymphomas: DLBCL, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
|